Ventyx Biosciences Reports Preclinical Data of VTX3232 in Murine Diet-Induced Obesity Models
Shots:
- Ventyx reported data from 2 preclinical diet-induced obesity (DIO) mice studies where DIO Study 1 assessed VTX3232 & semaglutide alone vs standard diet & DIO vehicle (high-fat diet) controls while DIO Study 2 assessed VTX3232 + semaglutide. The P-IIa trial is expected in H2’24
- Study 1 showed reduced body weight & food intake, decreased liver steatosis & triglycerides, improved cardiometabolic parameters (reduced cholesterol, insulin resistance, fasting blood glucose, HbA1c) & reduced systemic inflammatory biomarkers (IL-1β, IL-6, fibrinogen)
- Study 2 depicted higher benefits in body weight, liver steatosis & metabolic parameters, decreased systemic inflammatory biomarkers & improvement in body composition (reduced fat mass & increased lean mass percentage)
Ref: Ventyx | Image: Ventyx
Related News:- Ventyx Biosciences Reports P-II Trial Results of VTX002 for Moderate-to-Severely Active Ulcerative Colitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
